M. Cantarini

发表

A phase I study to determine the effect of tamoxifen on the pharmacokinetics of a single 250 mg oral dose of gefitinib (IRESSA) in healthy male volunteers

M. Cantarini, M. Macpherson, A. L. Marshall, 2005, Cancer Chemotherapy and Pharmacology.

EGFR mutation detection in ctDNA from NSCLC patient plasma: A cross-platform comparison of leading technologies to support the clinical development of AZD9291.

J Carl Barrett, Tracey Hammett, J. Barrett, 2015, Lung cancer.

Plasma ctDNA Analysis for Detection of the EGFR T790M Mutation in Patients with Advanced Non–Small Cell Lung Cancer

P. Jänne, T. Mitsudomi, S. Ramalingam, 2017, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Relative bioavailability and safety profile of gefitinib administered as a tablet or as a dispersion preparation via drink or nasogastric tube: results of a randomized, open-label, three-period crossover study in healthy volunteers.

M. Cantarini, A. L. Marshall, C. Bailey, 2004, Clinical therapeutics.

Osimertinib in patients with epidermal growth factor receptor T790M advanced non‐small cell lung cancer selected using cytology samples

K. Kiura, K. Yoh, I. Okamoto, 2018, Cancer science.

Metabolic Disposition of Osimertinib in Rats, Dogs, and Humans: Insights into a Drug Designed to Bind Covalently to a Cysteine Residue of Epidermal Growth Factor Receptor

P. Ballard, P. Dickinson, M. Cantarini, 2016, Drug Metabolism and Disposition.

Osimertinib Western and Asian clinical pharmacokinetics in patients and healthy volunteers: implications for formulation, dose, and dosing frequency in pivotal clinical studies

P. Jänne, M. Ranson, Y. Ohe, 2016, Cancer Chemotherapy and Pharmacology.

Title Page Metabolic Disposition of Osimertinib in Rat , Dog , and Man : insights into a drug designed to bind covalently to a cysteine residue of EGFR

P. Ballard, P. Dickinson, M. Cantarini, 2016 .

EGFR Mutation Analysis for Prospective Patient Selection in Two Phase II Registration Studies of Osimertinib

P. Jänne, F. Shepherd, J. Yang, 2017, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

A double-blind, randomized, incomplete crossover trial to assess the dose proportionality of rosuvastatin in healthy volunteers.

Paul D. Martin, A. Dane, M. Cantarini, 2003, Clinical therapeutics.

Comparison of the Pharmacokinetics of the Phase II and Phase III Capsule Formulations of Selumetinib and the Effects of Food on Exposure: Results From Two Randomized Crossover Trials in Healthy Male Subjects.

Paul D. Martin, Karen So, E. Lisbon, 2017, Clinical therapeutics.

Molecular Diagnostics

G. Ellison, C. Dive, R. Tuan, 2015, The Journal of the American Academy of Orthopaedic Surgeons.

Clinical activity of the mutant-selective EGFR inhibitor AZD9291 in patients (pts) with EGFR inhibitor–resistant non-small cell lung cancer (NSCLC).

P. Jänne, M. Ranson, M. Ahn, 2014 .

Detection of BRAF mutations in the tumour and serum of patients enrolled in the AZD6244 (ARRY-142886) advanced melanoma phase II study

M. Ranson, G. Ellison, C. Dive, 2009, British Journal of Cancer.

The effect of different etiologies of hepatic impairment on the pharmacokinetics of gefitinib

A. Harris, J. Carmichael, C. Twelves, 2011, Cancer Chemotherapy and Pharmacology.

Exploring the Relationship Between Expression of Cytochrome P450 Enzymes and Gefitinib Pharmacokinetics

H. Swaisland, R. Fuhr, M. Cantarini, 2006, Clinical pharmacokinetics.

The relative bioavailability of gefitinib administered by granular formulation

M. Cantarini, C. Bailey, Robert P. Smith, 2008, Cancer Chemotherapy and Pharmacology.

CNS response to osimertinib in patients with T790M-positive advanced NSCLC: pooled data from two phase II trials

P. Jänne, T. Mitsudomi, M. Ahn, 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

Plasma ctDNA analysis for detection of EGFR T790M mutation in patients (pts) with EGFR mutation‐positive advanced non‐small cell lung cancer (aNSCLC): 134O_PR

P. Jänne, T. Mitsudomi, S. Ramalingam, 2016, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

AZD6244 (ARRY-142886) vs temozolomide (TMZ) in patients (pts) with advanced melanoma: An open-label, randomized, multicenter, phase II study.

R. Dummer, J. Sosman, J. Kirkwood, 2008 .

Case studies showing clinical signs and management of cutaneous toxicity of the MEK1/2 inhibitor AZD6244 (ARRY-142886) in patients with solid tumours

W. T. van der Graaf, C. V. van Herpen, M. V. van Rossum, 2010, Acta oncologica.

Clinical evaluation of the potential drug–drug interactions of savolitinib: Interaction with rifampicin, itraconazole, famotidine or midazolam

G. Scarfe, W. Burke, K. Vishwanathan, 2021, British journal of clinical pharmacology.

Population pharmacokinetics and exposure‐response of osimertinib in patients with non‐small cell lung cancer

E. Cox, K. Vishwanathan, H. Witjes, 2017, British journal of clinical pharmacology.

Preliminary results of TATTON, a multi-arm phase Ib trial of AZD9291 combined with MEDI4736, AZD6094 or selumetinib in EGFR-mutant lung cancer.

M. Ahn, Y. Ohe, H. Saka, 2015 .

Effect of itraconazole on the pharmacokinetics of rosuvastatin

Paul D. Martin, A. Dane, Paul D. Martin, 2003, Clinical pharmacology and therapeutics.

Effect of oral linezolid on the pressor response to intravenous tyramine.

A. Hughes, M. Cantarini, C. Bolger, 2004, British journal of clinical pharmacology.

AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer.

P. Jänne, M. Ranson, M. Ahn, 2015, The New England journal of medicine.

Pharmacokinetics of gefitinib in humans: the influence of gastrointestinal factors.

H. Lennernäs, H. Swaisland, L. Knutson, 2007, International journal of pharmaceutics.

Osimertinib plus savolitinib in patients with EGFR mutation-positive, MET-amplified, non-small-cell lung cancer after progression on EGFR tyrosine kinase inhibitors: interim results from a multicentre, open-label, phase 1b study.

L. Sequist, M. Ahn, J. Yang, 2020, The Lancet. Oncology.

Acquired EGFR C797S mediates resistance to AZD9291 in advanced non-small cell lung cancer harboring EGFR T790M

Aleksandra Markovets, J Carl Barrett, Geoffrey R Oxnard, 2015, Nature Medicine.

AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer.

William Pao, Peter Ballard, Hailing Jin, 2014, Cancer discovery.

Osimertinib in Pretreated T790M-Positive Advanced Non-Small-Cell Lung Cancer: AURA Study Phase II Extension Component.

Chia-Chi Lin, Tomonori Hirashima, Helen Mann, 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Association Between Plasma Genotyping and Outcomes of Treatment With Osimertinib (AZD9291) in Advanced Non-Small-Cell Lung Cancer.

C. Paweletz, P. Jänne, J. Barrett, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Modulation of Biomarker Expression by Osimertinib: Results of the Paired Tumor Biopsy Cohorts of the AURA Phase I Trial

P. Jänne, L. Sequist, J. Wolf, 2017, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

449PDUPDATED SAFETY AND EFFICACY FROM A PHASE I STUDY OF AZD9291 IN PATIENTS (PTS) WITH EGFR-TKI-RESISTANT NON-SMALL CELL LUNG CANCER (NSCLC).

M. Ranson, E. Felip, D. Planchard, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

Selumetinib plus dacarbazine versus placebo plus dacarbazine as first-line treatment for BRAF-mutant metastatic melanoma: a phase 2 double-blind randomised study.

D. Schadendorf, R. Dummer, A. Arance, 2013, The Lancet. Oncology.

The First-in-Human Study of the Hydrogen Sulfate (Hyd-Sulfate) Capsule of the MEK1/2 Inhibitor AZD6244 (ARRY-142886): A Phase I Open-Label Multicenter Trial in Patients with Advanced Cancer

Paul D. Smith, D. Camidge, R. Agarwal, 2010, Clinical Cancer Research.

Acquired EGFR C 797 S mediates resistance to AZD 9291 in advanced non-small cell lung cancer harboring EGFR T 790 M

Yanan, C. Paweletz, J. Barrett, 2016 .

EGFR T790M mutation testing within the osimertinib AURA Phase I study.

P. Jänne, M. Ranson, H. Brown, 2017, Lung cancer.

A comparison of ARMS and DNA sequencing for mutation analysis in clinical biopsy samples

G. Ellison, G. Speake, G. McWalter, 2010, Journal of experimental & clinical cancer research : CR.

Circulating tumour-derived predictive biomarkers in oncology.

D. Hodgson, R. McCormack, M. Malone, 2010, Drug discovery today.

Analytical validation of BRAF mutation testing from circulating free DNA using the amplification refractory mutation testing system.

M. Ranson, G. Ellison, C. Dive, 2014, The Journal of molecular diagnostics : JMD.

Brief Report: Osimertinib Plus Durvalumab in Patients with EGFR-Mutated, Advanced Non-Small Cell Lung Cancer: A Phase 1b, Open-Label, Multicenter Trial.

P. Jänne, M. Ahn, B. Cho, 2022, Journal of Thoracic Oncology.

A Phase 1 Study to Evaluate Absolute Bioavailability and Absorption, Distribution, Metabolism, and Excretion of Savolitinib in Healthy Male Volunteers

G. Scarfe, K. Vishwanathan, M. Cantarini, 2023, Clinical pharmacology in drug development.

Phase II, Open-Label, Randomized Trial of the MEK1/2 Inhibitor Selumetinib as Monotherapy versus Temozolomide in Patients with Advanced Melanoma

R. Dummer, J. Larkin, J. Sosman, 2011, Clinical Cancer Research.

Preclinical Comparison of Osimertinib with Other EGFR-TKIs in EGFR-Mutant NSCLC Brain Metastases Models, and Early Evidence of Clinical Brain Metastases Activity

Matthew Grist, P. Jänne, K. Varnäs, 2016, Clinical Cancer Research.

Osimertinib in patients with T790M mutation‐positive, advanced non–small cell lung cancer: Long‐term follow‐up from a pooled analysis of 2 phase 2 studies

P. Jänne, L. Sequist, T. Mitsudomi, 2018, Cancer.

Osimertinib for pretreated EGFR Thr790Met-positive advanced non-small-cell lung cancer (AURA2): a multicentre, open-label, single-arm, phase 2 study.

T. Mitsudomi, F. Shepherd, L. Crinò, 2016, The Lancet. Oncology.

Selumetinib ( AZD 6244 , ARRY ‐ 142886 ) in Patients with Solid Tumors

W. Oyen, W. Graaf, I. Desar, 2019 .

18F-FLT-PET for Response Evaluation of MEK Inhibitor Selumetinib (AZD6244, ARRY-142886) in Patients with Solid Tumors

W. Oyen, C. V. van Herpen, I. Desar, 2012, World journal of nuclear medicine.

The first-in-human study of the solid oral dosage form of AZD6244 (ARRY-142886): A phase I trial in patients (pts) with advanced cancer

D. Camidge, R. Agarwal, U. Banerji, 2008 .

Pharmacokinetics of Osimertinib in Chinese Patients With Advanced NSCLC: A Phase 1 Study

Jian-hua Chang, Li Zhang, Hongyun Zhao, 2018, Journal of clinical pharmacology.

Osimertinib (AZD9291) in pre‐treated pts with T790M‐positive advanced NSCLC: updated Phase 1 (P1) and pooled Phase 2 (P2) results: LBA2_PR

P. Jänne, T. Mitsudomi, S. Ramalingam, 2016, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Osimertinib + Savolitinib to Overcome Acquired MET-Mediated Resistance in Epidermal Growth Factor Receptor–Mutated, MET-Amplified Non–Small Cell Lung Cancer: TATTON

Jie Yang, L. Sequist, M. Ahn, 2022, Cancer discovery.

The effect of fluconazole on the pharmacokinetics of rosuvastatin

A. Dane, M. Cantarini, D. Schneck, 2002, European Journal of Clinical Pharmacology.

Impact of Disease and Treatment Response in Drug–Drug Interaction Studies: Osimertinib and Simvastatin in Advanced Non‐Small Cell Lung Cancer

Karen So, S. Ramalingam, R. Harvey, 2019, Clinical and translational science.

FP14.03 Osimertinib + Savolitinib in pts with EGFRm MET-Amplified/Overexpressed NSCLC: Phase Ib TATTON Parts B and D Final Analysis

P. Jänne, L. Sequist, J.-Y. Han, 2021 .

A randomized phase II clinical trial of the SRC inhibitor saracatinib (AZD0530) and carboplatin plus paclitaxel (C plus P) versus C plus P in patients (pts) wiht advanced platinum-sensitive epithelial ovarian cancer (eoc)

Gunnar B. Kristensen, S. Rodenhuis, C. Poole, 2010 .

Osimertinib plus selumetinib in EGFR-mutated, non-small cell lung cancer after progression on EGFR-TKIs: A Phase 1b, open-label, multicenter trial (TATTON Part B).

P. Jänne, M. Ahn, Y. Ohe, 2022, Clinical cancer research : an official journal of the American Association for Cancer Research.

Abstract CT303: The effect of savolitinib plus osimertinib on ctDNA clearance in patients with EGFR mutation positive (EGFRm)MET-amplified NSCLC in the TATTON study

M. Ahn, B. Cho, Ji-Youn Han, 2020 .

CNS response to osimertinib in patients (pts) with T790M-positive advanced NSCLC: Data from a randomized phase III trial (AURA3).

M. Ahn, T. Mok, Yi-long Wu, 2017 .

MA16.11 CNS Response to Osimertinib in Patients with T790M-Positive Advanced NSCLC: Pooled Data from Two Phase II Trials

P. Jänne, T. Mitsudomi, M. Ahn, 2017 .

TATTON expansion cohorts: A phase Ib study of osimertinib plus savolitinib in patients (pts) with EGFR-mutant, MET-positive NSCLC following disease progression on a prior EGFR-TKI

L. Sequist, M. Ahn, W. Su, 2019, Annals of Oncology.

A Phase 1b Study of Osimertinib Plus Savolitinib in Patients with EGFR Mutation-Positive, MET-Amplified, Non-Small Cell Lung Cancer after Progression on EGFR-Tyrosine Kinase Inhibitors

L. Sequist, M. Ahn, J. Yang, 2019, SSRN Electronic Journal.

LBA3A PHASE I STUDY OF AZD9291 IN PATIENTS WITH EGFR-TKI-RESISTANT ADVANCED NSCLC – UPDATED PROGRESSION FREE SURVIVAL AND DURATION OF RESPONSE DATA

P. Jänne, M. Ahn, D. Planchard, 2015 .

456PPRECLINICAL EVIDENCE AND CLINICAL CASES OF AZD9291 ACTIVITY IN EGFR-MUTANT NON-SMALL CELL LUNG CANCER (NSCLC) BRAIN METASTASES (BM).

P. Janne, D. Cross, P. Ballard, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

Do gastrointestinal transit parameters influence the pharmacokinetics of gefitinib?

H. Swaisland, P. Dickinson, S. Connolly, 2009, International journal of pharmaceutics.

AZD9291, a mutant-selective EGFR inhibitor, as first-line treatment for EGFR mutation-positive advanced non-small cell lung cancer (NSCLC): Results from a phase 1 expansion cohort.

P. Jänne, Y. Ohe, S. Ramalingam, 2015 .

Osimertinib combined with durvalumab in EGFR‐mutant non‐small cell lung cancer: Results from the TATTON phase Ib trial: 136O

M. Ahn, H. Saka, S. Ramalingam, 2016, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

3083 AZD9291 activity in patients with EGFR-mutant advanced non-small cell lung cancer (NSCLC) and brain metastases: Data from Phase II studies

P. Jänne, T. Mitsudomi, M. Ahn, 2015 .

An investigation of components of variance and tachyphylaxis in a placebo-controlled intravenous tyramine study.

A. Hughes, J. Growcott, M. Cantarini, 2004, British journal of clinical pharmacology.

SAVANNAH: A Phase II trial of osimertinib plus savolitinib for patients (pts) with EGFR-mutant, MET-driven (MET+), locally advanced or metastatic non-small cell lung cancer (NSCLC), following disease progression on osimertinib.

M. Ahn, G. Oxnard, R. Hartmaier, 2019, Journal of Clinical Oncology.

AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer.

W. Pao, M. Ranson, Hailing Jin, 2014, Cancer discovery.

AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer.

P. Jänne, M. Ranson, M. Ahn, 2015, The New England journal of medicine.

Azd9291, an Irreversible Egfr Tki, Overcomes T790m-mediated Resistance to Egfr Inhibitors in Lung Cancer Oncology Innovative Medicines And

W. Pao, D. Cross, R. Rowlinson, 2022 .